Experimental Exercise Mimetic

SLU-PP-332

Pan-ERR Agonist • Synthetic Small Molecule

SLU-PP-332 is an experimental small molecule—not a peptide—that activates estrogen-related receptors involved in mitochondrial biogenesis, fatty-acid oxidation, energy expenditure, and exercise adaptation. All in-vivo efficacy evidence currently comes from mouse studies.

Exercise Mimetic Fat Oxidation Mitochondria Preclinical Only

Protocol Snapshot

SLU-PP-332 Quick Reference

Verified Vendors

SLU-PP-332

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Community Range

20–100mg

Daily oral or sublingual reports; not clinically validated.

Reported Cycle

4–8 Weeks

Anecdotal practice only.

Evidence

Preclinical

No published living-human trial.

Community Route

Oral / Sublingual

Human bioavailability remains unquantified.

Peptide Grade

GradeD

Mouse studies show ERR-driven endurance, metabolic, cardiac, and renal signals, but zero published living-human trials, unquantified oral exposure, and no human safety framework sharply limit practical confidence.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What Is SLU-PP-332?

SLU-PP-332 is not a peptide. It is a synthetic small molecule with the chemical formula C18H14N2O2 and a molecular weight of approximately 290.32g/mol.

The compound was developed at Saint Louis University as an agonist of estrogen-related receptors, commonly abbreviated ERRs. Despite the name, these receptors do not bind estrogen and activating them does not directly raise estrogen levels.

There are three major ERR subtypes: ERR alpha, ERR beta, and ERR gamma. SLU-PP-332 activates all three and is therefore described as a pan-ERR agonist, with its strongest activity generally associated with ERR alpha.

Not a Replacement for Exercise

Exercise activates hundreds of pathways involving AMPK, mTOR, BDNF, IGF-1, myokines, bone signaling, immune adaptation, and more. SLU-PP-332 targets only one part of that larger system.

SLU-PP-332 Benefits

All demonstrated benefits come from mouse studies or in-vitro human cell work. There is no human efficacy data.

Exercise Capacity

Treated mice ran approximately 70% longer and 45% farther than controls after repeated dosing in the original exercise-capacity study.

Fat Loss

Obese mice lost about 12% of body weight over 28 days without eating less or becoming more active.

Mitochondrial Biogenesis

ERR activation increased mitochondrial DNA content and shifted muscle toward more oxidative fiber characteristics.

Glucose Regulation

Mouse studies reported improved glucose tolerance and insulin sensitivity alongside increased energy expenditure.

Kidney Protection

Aging-mouse research reported improvements in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory markers.

Cardiac Metabolism

In pressure-overload heart-failure mice, treatment improved ejection fraction, reduced fibrosis, and increased survival.

Protocol Planning

Dosing, cycling, and preparation

SLU-PP-332 Dosing Protocol

No human clinical trial has established a safe or effective dose. The range below is based only on anecdotal community use and should not be treated as validated medical dosing.

Community-Reported Range

Low Range

20–30mg daily

Moderate Range

40–60mg daily

High Range

80–100mg daily

Frequency

Once daily or divided into two doses

Cycle

Commonly discussed for 4–8 weeks

Evidence Limits

Human Trials

None published

Dose Response

Not established in humans

Oral Exposure

Unquantified and likely formulation-dependent

Pharmacokinetics

No human data

Long-Term Safety

Unknown

Formulation & Handling

SLU-PP-332 is not water-soluble. Bacteriostatic water does not create a true solution and should not be treated as a valid reconstitution method.

Why Peptide Reconstitution Does Not Apply

Solubility

Insoluble in water

BAC Water

Does not create a true solution

Result

Particles remain suspended rather than dissolved

Dose Accuracy

Unreliable when the compound is not in solution

Published vs Community Routes

Mouse Studies

Intraperitoneal administration using laboratory vehicle systems

Injectable Human Use

No validated preparation or dosing protocol

Community Routes

Oral capsules and sublingual products are most often discussed

Human Exposure

Bioavailability has not been quantified

Oral Formulation Limits

No formal human oral-bioavailability study has established how much SLU-PP-332 reaches circulation from capsules or sublingual products. Its poor water solubility makes exposure likely to depend on formulation and individual absorption, which may help explain the unusually inconsistent community reports.

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Improved endurance, better training focus, and gradual fat loss are occasionally reported.
A minority report visible body-composition changes over four to eight weeks.
Improved recovery and exercise tolerance are reported by some users.

Negative Reports

Many users report absolutely no noticeable effect.
Results remain inconsistent across capsules, sublingual products, and improvised liquid preparations.
Fatigue, sleep disturbance, gastrointestinal discomfort, and possible blood-sugar drops are occasionally reported.
Some users report a higher heart rate or feeling unusually taxed during cardio.
Reports that dietary fat or sublingual use improves consistency highlight the unresolved absorption problem rather than a reliable benefit.

Stacking & Synergy

Potential SLU-PP-332 pairings and tracking context

Relevant Combinations

SLU-PP-332 + GLP-1 Agonists

In theory, ERR activation may increase energy expenditure while GLP-1 agonists reduce appetite. No published combination study has established benefit or safety.

SLU-PP-332 + MOTS-c

MOTS-c acts largely through AMPK-related signaling, while SLU-PP-332 activates ERRs. The combination is mechanistically interesting but unstudied.

SLU-PP-332 + SS-31

SS-31 targets the inner mitochondrial membrane, while SLU-PP-332 influences mitochondrial gene expression. No combination data exists.

Training & Nutrition

No compound replaces exercise. Resistance training, cardio, protein intake, and calorie control remain the evidence-based foundation.

Free with login

Track in Journal

Track SLU-PP-332 with the markers that matter most for this compound.

Endurance, pace, and perceived exertion.
Resting and training heart-rate response.
Weight, waist, sleep, and GI tolerance.

Start Tracking

Common Questions

Practical SLU-PP-332 answers

Is SLU-PP-332 a peptide?

No. It is a synthetic small-molecule pan-agonist of estrogen-related receptors.

Has it been tested in living humans?

No published living-human clinical trial has established efficacy, pharmacokinetics, dose response, or safety.

Can it be mixed with BAC water?

No. Its poor water solubility means bacteriostatic water does not create a true, dose-uniform solution.

Why are community reports so inconsistent?

Unquantified oral exposure, formulation differences, and uncertain product content make nominal doses difficult to compare.

Safety Notes

Side effects, contraindications, and precautions

SLU-PP-332 Side Effects

No human clinical safety data exists. The longest published animal treatment period was eight weeks, which is not enough to establish chronic safety.

The main concern is not a proven toxicity—it is the number of unanswered questions. Human pharmacokinetics, organ toxicity, reproductive safety, cancer risk, drug interactions, and long-term metabolic effects remain unknown.

In Published Research

HDL cholesterol decreased in the metabolic-syndrome mouse study.
No long-term cancer, fertility, or organ-safety studies have been completed.
No human adverse-event database exists.

What Users Report

Fatigue, sleep disturbance, mild GI discomfort, and feeling unusually winded during exercise are reported.
Possible hypoglycemia has been reported, especially with fasting or other glucose-lowering compounds.
Many users report no effect at all, which may reflect poor or inconsistent absorption.

SLU-PP-332 Precautions

Major Precautions

Known hypersensitivity to SLU-PP-332 or formulation ingredients.
Pregnancy or breastfeeding because no reproductive-safety data exists.

Use Caution With

Active malignancy, an unevaluated tumor, or prior cancer history. ERR biology is relevant to some cancers, but SLU-PP-332 has no human cancer-risk data.
Diabetes, hypoglycemia, or medications that lower blood sugar.
Abnormal cholesterol, especially low HDL.
Cardiovascular disease, arrhythmias, or unexplained exercise intolerance.
Liver or kidney impairment because human metabolism and clearance are unknown.

Drug Interactions

No formal human interaction studies exist. Glucose-lowering medications and compounds deserve particular caution because increased metabolic demand may increase hypoglycemia risk.

Monitoring

No validated monitoring protocol exists. Relevant markers would include fasting glucose, lipids, liver and kidney function, heart rate, blood pressure, exercise tolerance, and unexplained weight loss or fatigue.

Regulatory Status

SLU-PP-332 is not FDA approved and has not entered a published human clinical trial. It falls under WADA's S0 non-approved substances category and is prohibited in tested sport.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

On the surface, SLU-PP-332 sounds interesting. In practice, the story is far less compelling. Early vendors commonly sold capsules containing just 250mcg or 500mcg—amounts that, in our experience, did little beyond generating placebo-level expectations. That mismatch between the products being sold and the much larger doses discussed in research communities helps explain why SLU-PP-332 was bashed so heavily online.

Community dosing discussions eventually shifted toward 20mg or more, but that created a major cost problem. When a bottle of 60 capsules costs $150 or more, reaching those amounts becomes prohibitively expensive. Vendors have since started offering 20mg capsules, which is a huge improvement over the original microgram products, but prices approaching $200 still make little sense when alternatives such as MOTS-c have more supporting evidence and broader practical use.

Add SLU-PP-332's poor water solubility and the complete absence of human safety data, and the assigned grade becomes easy to justify. We have tested this product ourselves and would not buy it again.

The final nail in the coffin is SLU-PP-915, a newer compound introduced by researchers involved with SLU-PP-332 and positioned as having improved oral exposure. It is difficult not to view that development as an indirect acknowledgment that the original compound's oral bioavailability was a fundamental limitation. SLU-PP-332 may remain scientifically interesting, but as a practical community compound, the cost, uncertain absorption, and lack of human data make it exceptionally difficult to recommend.